Ku ya 27 Nyakanga 2023, Lilly yatangaje ko ubushakashatsi bwa Mount-3 bwerekeye Tirzepatide yo kuvura abarwayi bafite umubyibuho ukabije ndetse n’ubushakashatsi bwakozwe na Mount-4 bwo gukomeza kugabanya ibiro by’abarwayi bafite umubyibuho ukabije bugeze ku ndunduro y’ibanze ndetse n’ingenzi byanyuma.Nubushakashatsi bwa gatatu nubwa kane bwatsinze icyiciro cya III cyabonetse na Tirzepatide nyuma yumusozi-1 na Mount-2.
SURMOUNT-3 (NCT04657016) ni ikigo kinini, giteganijwe, gihumye-impumyi, kibangikanye, kigenzurwa na platbo cyandika abantu 806 bitabiriye igamije kwerekana ko Tirzepatide iruta umwanya wa platbo ukurikije ihinduka ry’ijanisha ry’imihindagurikire y’ibiro nyuma yo guhitamo no ku ijanisha rya abitabiriye batakaje ≥5% nyuma yo gutoranya ibyumweru 72.
Ibyavuye mu bushakashatsi bwa SURMOUNT-3 byerekanye ko Tirzepatide yujuje ibisobanuro byose, ni ukuvuga ko nyuma y’ibyumweru 72 bivura imiti, abarwayi bo mu itsinda rya Tirzepatide bageze ku ijanisha ryinshi ry’ibiro bivuye ku murongo ugereranije na placebo, naho umubare munini w’abarwayi bo mu itsinda rya Tirzepatide yageze ku ijanisha ry'ibiro birenze 5%.Amakuru yihariye y’amavuriro yerekanaga ko abarwayi bavuwe na Tirzepatide batakaje impuzandengo ya 21.1% yuburemere bwumubiri ugereranije na placebo;Ugereranije nigihe cyo gutabara ibyumweru 12, abarwayi bavuwe na Tirzepatide batakaje ikigereranyo cya 26,6% byuburemere bwumubiri.Byongeye kandi, 94,4% by'abarwayi batakaje ≥5% by'uburemere bwabo mu itsinda rya Tirzepatide, ugereranije na 10.7% mu itsinda rya placebo.
SURMOUNT-4 (NCT04660643) ni ikigo kinini, giteganijwe, gihumye-impumyi, kibangikanye, kigenzurwa na platbo cyandikirwa abantu 783 bitabiriye kwerekana ko Tirzepatide yarutaga umwanya wa platbo mu guhindura ibiro ku ijanisha ry’ibyumweru 88.
Ibisubizo byerekanye ko nyuma yigihe cyimpumyi zibiri zibyumweru 37 ~ 88, abarwayi bo mumatsinda ya Tirzepatide batakaje ibiro byinshi ugereranije nitsinda rya placebo.Ku bijyanye n’umutekano, ntabwo ubushakashatsi bwa SURMOUNT-3 cyangwa SURMOUNT-4 bwerekanye ibimenyetso bishya by’umutekano.
Kuva hatangizwa ibiyobyabwenge bya Novo Nordisk byangiza ibiryo Semaglutide, bifatanije n’uko Musk abishimangira, byahindutse ibicuruzwa byamamare kuri interineti ndetse n’umwami ugabanya ibiro muri iki gihe.Isoko ryo kugabanya ibiro birakenewe cyane, kandi hariho imiti ibiri gusa ya GLP-1 yo kugabanya ibiro kurubu ku isoko, Liraglutide na Semaglutide, ariko Liraglutide ni imyiteguro yigihe gito, idashobora guhangana nimyiteguro yigihe kirekire mubijyanye no kubahiriza abarwayi , hamwe no kugabanya ibiro byisi byigihe gito ni ibya Semaglutide.
Umwami wumurima wa GLP-1, Lilly yifuza inyanja yubururu yisoko ryo kugabanya ibiro - nuko Lilly atangiza ikibazo maze abanza gutega Tirzepatide gufata umwanya mwisoko ryo kugabanya ibiro.
Tirzepatide ni buri cyumweru GIPR / GLP-1R ya agonist, GIP (glucose-iterwa na insuline itera polypeptide) ni undi munyamuryango wumuryango wa glucagon peptide, hamwe ningaruka zo guteza imbere insuline mu buryo buterwa na insuline no gutera ururenda rwa glucagon muri hypoglycemic leta, GIPR / GLP-1R dual agonist irashobora kubyara isukari yamaraso, kugabanya ibiro nizindi ngaruka mukangura GIP na GLP-1 kumanuka.Tirzepatide yemerewe na FDA mu 2022-5 (izina ry'ubucuruzi: Mounjaro) kugira ngo ikoreshwe ifatanije n'indyo n'imyitozo ngororamubiri kugira ngo igabanye indwara ya glycemic ku bantu bakuru barwaye diyabete yo mu bwoko bwa 2.
Igihe cyo kohereza: Nzeri-18-2023